GS

GSK

Every trial this sponsor leads in the registry, and everything it has published.

3,722All trials
Recruiting83
Recruited74
Not yet recruiting36
Completed3,144
Stopped373
Other12

193 active · 5% of this sponsor’s registry footprint

Oncology72 trials
Infectious Disease56 trials
Respiratory27 trials
Gastroenterology & Hepatology9 trials
Immunology & Inflammation7 trials
ENT & Hearing3 trials
Metabolic/Endocrine/Nutrition3 trials
Neurology2 trials

Not shown above: 10 trials whose condition matched no therapy area.

Trials by phase

Phase 11,297
Phase 2903
Phase 31,002
Phase 4369
Unphased151

Pipeline by phase · 81 drugs in active development

Phase 3 · 25 drugs

Belantamab mafodotin19 trials · 3 recruitingest. Feb 2029
GSK57842838 trials · 2 recruitingest. Apr 2027
Efimosfermin Alfa7 trials · 5 recruitingest. Oct 2027
Mocertatug rezetecan5 trials · 3 recruitingest. Sept 2027
Risvutatug Rezetecan5 trials · 4 recruitingest. Nov 2027
CAB LA3 trialsest. Mar 2027
Camlipixant (BLU-5937)3 trials · 2 recruitingest. Mar 2027
Velzatinib (IDRX-42)3 trials · 3 recruitingest. Nov 2027

Phase 2 · 19 drugs

Bepirovirsen3 trialsest. Apr 2027
Cobolimab (TSR-022)3 trialsest. Oct 2026
GSK3862995B3 trials · 2 recruitingest. Dec 2026
Momelotinib3 trials · 2 recruitingest. Mar 2027
VH45241843 trials · 3 recruitingest. Jun 2027
Adjuvanted RSVPreF3 vaccine2 trialsest. Jan 2027
GSK45329902 trials · 1 recruitingest. Nov 2027
Nivisnebart (GSK4527226)2 trials · 1 recruitingest. Sept 2026

Phase 1 · 29 drugs

Pn-MAPS30plus3 trials · 1 recruitingest. Dec 2026
Cabotegravir2 trials · 1 recruitingest. Oct 2029
Gepotidacin2 trialsest. May 2027
GSK47712612 trialsest. Sept 2026
GSK59263712 trials · 1 recruitingest. Mar 2028
Cabotegravir 200 mg/mL1 trial · 1 recruitingest. Jun 2027
Candidate UTI vaccine low dose formulation 11 trial · 1 recruitingest. May 2027
Dolutegravir/Rilpivirine FDC1 trial · 1 recruiting

Phase 4 · 8 drugs

Dostarlimab15 trials · 4 recruitingest. Nov 2026
Depemokimab9 trials · 8 recruitingest. Sept 2026
Belimumab5 trials · 3 recruitingest. Jun 2027
Niraparib5 trials · 1 recruitingest. Dec 2026
Mepolizumab1 trial
Recombinant zoster vaccine1 trial · 1 recruitingest. Apr 2030
rMenB+OMV NZ1 trial

Active trials only, code names and brands merged. 3,144 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 4 of 10 curated

Multiple myeloma (Oncology)20 trials · 3 recruiting · 2 drugs2.6% of landscape
Non-small cell lung cancer (Oncology)6 trials · 3 drugs0.4% of landscape
Breast cancer (Oncology)3 trials · 1 recruiting · 2 drugs0.1% of landscape
Alzheimer's disease (Neurology)1 trial · 1 recruiting · 1 drug0.3% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon